Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

NCT00700336 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Pleural Mesothelioma
Solid Tumors

Interventions

DRUG: pemetrexed, cisplatin and CBP501
DRUG: pemetrexed and cisplatin
DRUG: pemetrexed, cisplatin and CBP501, dose finding

Sponsor

CanBas Co. Ltd.